Exosomes Displaying ACE2 Protein for SARS-CoV-2 Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods and compositions to treat and prevent SARS-CoV-2 infections, as current therapeutics are lacking, and existing approaches do not provide broad neutralization against SARS-CoV-2 viral strains.
Innovation Solution
The development of exosomes comprising the ACE2 protein, viral spike protein, or virus-neutralizing immunoglobulin G (IgG) variants, which are administered to subjects to treat or prevent SARS-CoV-2 infection, optionally loaded with additional therapeutic agents like remdesivir, and engineered to display these proteins on their surface for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exosomes are engineered to display ACE2 protein or viral spike protein on their surface, then the neutralization capability against SARS-CoV-2 is improved, but the manufacturing complexity increases
Solution Approach 1:
The exosome therapy is segmented into different functional components: exosomes displaying ACE2 protein for blocking viral entry, exosomes displaying viral spike protein for immunogenicity, and exosomes loaded with therapeutic agents like remdesivir. This segmentation allows each component to perform its specific function while simplifying the overall manufacturing process by producing and combining separate functional units rather than creating a single complex multi-functional exosome.
Solution Approach 2:
The exosome platform is designed with multi-functionality, where a single exosome can potentially perform multiple functions: displaying ACE2 protein for viral entry blocking, presenting viral antigens for immune stimulation, and carrying therapeutic drugs. This universality reduces the need for multiple separate therapeutic agents and simplifies treatment protocols, though it requires sophisticated engineering capabilities.
2Reliability
If exosomes are loaded with additional therapeutic agents like remdesivir, then the treatment efficacy is improved, but the loss of substance increases
Solution Approach 1:
Therapeutic agents such as remdesivir are nested within the exosome structure, either in the exosomal lumen or incorporated into the exosome membrane. This nesting allows the therapeutic agent to be protected from degradation and loss, while maintaining its efficacy. The exosome acts as a protective container that prevents premature release or loss of the therapeutic substance, thereby reducing the apparent loss while maintaining treatment effectiveness.
3Adaptability or versatility
If exosomes are engineered with viral spike protein or mRNAs/cDNAs, then the adaptability against viral strains is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The exosome therapy incorporates dynamic elements through the inclusion of mRNA or cDNA that can be translated into viral spike protein variants. This allows the therapeutic to adapt to different viral strains dynamically, rather than being fixed for a specific strain. The manufacturing process accommodates this dynamic adaptability by using standardized platforms that can be reconfigured with different mRNA sequences targeting various viral variants, thereby maintaining precision while achieving versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The exosomes effectively neutralize SARS-CoV-2 infections by binding to the viral spike protein, inhibiting viral entry into host cells, and demonstrate significant neutralization capabilities against various SARS-CoV-2 strains, including severe forms of the virus, thereby providing a promising treatment and prevention strategy.
Implementation Method 1
The exosomes effectively neutralize SARS-CoV-2 infections by binding to the viral spike protein
Data Source
AI summary
Disclosed herein are exosomes, compositions, and methods for the treatment of subjects infected with, or at risk for infection with a coronavirus, such as SARS-COV-2, HCoV-NL63, or SARS-COV. The disclosed exosomes comprise ACE2 protein and typically display ACE2 protein on the exosome surface. In some embodiment, the exosomes optionally are loaded with one or more additional therapeutic agents for treating an infection by a coronavirus, such as remdesivir. In some embodiments, compositions comprising the exosomes are administered to a subject in need thereof, e.g., to a subject diagnosed with, or suspected of having a SARS-COV-2 infection, an HCoV-NL63 infection, or a SARS-COV infection. In some embodiments, administration is via inhalation. In some embodiments, administration is via injection.